Table 3.

Comparison of lipid subgroup analyses in fibrate trials.

Study (drug)	CVD reduction -entire cohort (p-value)	Lipid subgroup HDL-C criteria	Lipid subgroup triglyceride criteria	CVD reduction – lipid subgroup (p-value)	Ref.
HHS (gemfibrozil)	−34% (0.02)	<1.09 mmol/l (<42 mg/dl)†	≥2.31 mmol/l (≥204 mg/dl)	−78% (0.002)	[36,42]
VA-HIT (gemfibrozil)	−22% (0.006)	-	≥2.03 mmol/l (≥180 mg/dl)	−28% (<0.05)	[39,44]
BIP(bezafibrate)	−7.3% (0.24)	-	≥2.26 mmol/l (≥200 mg/dl)	−39.5% (0.02)	[40]
FIELD (fenofibrate)	−11% (0.16)	Men: <1.04 mmol/l (<40 mg/dl) Women <1.30 mmol/l (<50 mg/dl)	≥2.31 mmol/l (≥204 mg/dl)	−27% (0.005)	[25,49]
ACCORD (fenofibrate)	−8% (0.26)	≤0.88 mmol/l (≤34 mg/dl)	≥2.31 mmol/l (≥204 mg/dl)	−31% (0.032)	[4,54]

Percentage reductions in cardiovascular event rates within fibrate trials are presented for both the entire study cohort and subgroups defined by hypertriglyceridemia and/or low HDL-C There is a consistent finding of reduced cardiovascular outcomes in these trials in subgroups defined by the presence of hypertriglyceridemia and low HDL-C regardless of whether the overall outcome was positive or negative.

^†BMI >26 kg/m².

CVD: Cardiovascular disease.